Pay in 4 interest-free payments of $5.93 Learn more
Ships within 48 hours · Estimated delivery Sep 22 - Sep 27
On the basis of results of the most recent CVOTs (DAPA-HF, DAPA-CKD, EMPEROR-R), the FDA has approved dapagliflozin (2020) and empagliflozin (2021) to reduce risk for CV death and HF hospitalization in adults with HF and reduced ejection fraction regardless of whether they have diabetes [24, 25]
Employers would save on sick days, burnout, and the downstream costs of managing chronic diseases that are directly tied to obesity
Compared to popular GLP-1RAs like semaglutide, orforglipron does not require injection or an absorption enhancer with fasting to achieve exposure, and it can be taken without water or food restrictions, according to Phase 1 pharmacokinetic data
These discussions often center on everyday experiences with GLP-1 medications, including how dosing choices affect comfort, cost, and consistency
JAMA Intern Med 2013;173:534-9.ArticlePubMed 60
Average weight loss in pooled trials is around 4 pounds
